, since epidemiologic studies consistently suggest an environmental pathogen(s) as an antecedent for MS (1, 5) . Recent studies implicating a viral association of human herpesvirus 6 with MS plaques (6) also lend support to this hypothesis. Resistance to TMEV-induced demyelination is associated with specific alleles at the class I H2D region (32) and is further associated with differential regulation of class I products and the presence of virus-specific cytotoxic CD8 ϩ T cells (CTL) in central nervous system-infiltrating lymphocyte (CNS-IL) populations (10, 24, 28, 31) . We previously determined that the VP2 capsid protein of TMEV is a prominent target of H2D b -restricted CTLs (17). We also determined that cytolytic CD8 ϩ T cells are required for clearance of TMEV in resistant mouse strains (10, 24, 28, 31) . The only TMEV-VP2 epitope identified to date is VP2 from positions 74 to 86 (VP2 [74][75][76][77][78][79][80][81][82][83][84][85][86] ), which is a major histocompatibility complex (MHC) class IIrestricted epitope encoded by another TMEV strain (BeAn) and recognized by T-helper cells in susceptible SJL/J mice (12).
Mice expressing the H2 b, d, or k haplotypes effectively clear an intracerebral injection of the Daniels (DA) substrain of Theiler's murine encephalomyelitis virus (TMEV), whereas susceptible strains (H2 s, q, r, v, f, or p haplotypes) develop persistent viral infection. The latter, TMEV-susceptible mouse strains, develop a chronic, progressive form of demyelination similar both clinically and pathologically to human multiple sclerosis (MS). TMEV-infected mice provide an excellent model for the study of MS (33) , since epidemiologic studies consistently suggest an environmental pathogen(s) as an antecedent for MS (1, 5) . Recent studies implicating a viral association of human herpesvirus 6 with MS plaques (6) also lend support to this hypothesis. Resistance to TMEV-induced demyelination is associated with specific alleles at the class I H2D region (32) and is further associated with differential regulation of class I products and the presence of virus-specific cytotoxic CD8 ϩ T cells (CTL) in central nervous system-infiltrating lymphocyte (CNS-IL) populations (10, 24, 28, 31) . We previously determined that the VP2 capsid protein of TMEV is a prominent target of H2D b -restricted CTLs (17) . We also determined that cytolytic CD8 ϩ T cells are required for clearance of TMEV in resistant mouse strains (10, 24, 28, 31) . The only TMEV-VP2 epitope identified to date is VP2 from positions 74 to 86 (VP2 [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] ), which is a major histocompatibility complex (MHC) class IIrestricted epitope encoded by another TMEV strain (BeAn) and recognized by T-helper cells in susceptible SJL/J mice (12) .
The reproducibility of identifying VP2 region-specific, D b -restricted CTL in CNS-IL populations from TMEV-infected mice suggested a prominent role for the CTL response to the VP2 antigen in virus clearance. Accordingly, the VP2 antigen should include at least one peptide that complexes with D b molecules and is efficiently recognized by these CTL. An understanding of the fundamental difference between mice resistant and susceptible to TMEV infection, the former of which require CD8
ϩ CTLs for efficient virus clearance, depends on the identification of prominent peptides recognized by CTL restricted by class I genes associated with resistant H2 haplotypes.
The goal of the present work was to identify a VP2-associated peptide that complexes with D b molecules and is recognized by CNS-ILs from TMEV-infected resistant mice. A method for insertion of variable lengths of VP2 into a prokaryotic fusion protein gene followed by random base hydrolysis (11) led to the identification of a 10-amino-acid peptide that binds to D b molecules and is recognized by freshly harvested CNS-ILs from TMEV-infected mice. The amino acid sequence of this peptide starkly contrasts with those of other identified D b -binding peptides in its lack of an Asn at residue 5 which has been proposed to be part of an essential motif for D b -binding peptides (8, 9, 29) .
MATERIALS AND METHODS
PCR product generation. The template for variable-length VP2 PCR products was pDAFL3 plasmid (25) , which includes the full-length sequence of the DA strain of TMEV (accession no. M20301). The left-hand primer VP2 Anchor (5-ACCGA GCTCGGATCCAGATCAAAACACAGAGGAGATGG-3) contains VP2 bases 1507 to 1528 at the 3Ј end and a BamHI site at the 5Ј end. This primer was used with 11 right-hand primers (ranging from 18 to 21 bp), including XhoI sites at their 5Ј ends, that allowed amplification of VP2 PCR products of increasing lengths (Fig. 1) . The first 9 fragments increased sequentially by 60 bp, and the 10th and 11th fragments increased by 120 and 81 bp, respectively, as indicated in Fig. 1 . The PCR was conducted with HotStart 50 reaction tubes according to the recommended protocol of the manufacturer (Molecular Bio-Products, Inc., San Diego, Calif.). All reaction mixtures included 20 pmol of each primer, 10 ng of template pDAFL3, and 0.25 l of Taq DNA polymerase (Promega, Madison, Wis.). Cycling parameters were 25 rounds of 1 min of denaturation at 94°C, 1 min of annealing at 55°C, and extension for 1 min at 72°C. An initial round was denatured for 5 min, and a final round was extended for 7 min. All reactions were performed with a DNA Thermo-Cycler (Perkin-Elmer Cetus, Foster City, Calif.).
Plasmid construction and fusion protein expression. Recombinant DNA manipulations were performed according to standard protocols (2). The 11 PCR products were unidirectionally cloned into the BamHI and XhoI sites of pET17xb (Novagen, Madison, Wis.) by placing each product in frame with the N-terminal and C-terminal sequences of the proprietary fusion protein (Fig. 1) . Transformation hosts were NovaBlue cells selected for plasmid maintenance and BL21(DE3) cells (Novagen) for inducible T7 RNA polymerase transcription and subsequent fusion protein expression. Transformants in both hosts were selected for carbenicillin resistance according to the manufacturer's instructions. Inserts and cloning sites were sequenced on an ABI 373-A Automated Sequencer with an ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction kit (PerkinElmer). Twenty-milliliter cultures in Luria-Bertani medium (LB) plus carbenicillin (100 g/ml) were initiated with a fresh overnight colony from each cloning. Cells in mid-log growth were induced with isopropyl-␤-D-thiogalactopyranoside (IPTG) (final concentration, 0.4 mM) and grown for 3.5 h postinduction. Fusion protein synthesis was confirmed with 500-l samples taken every 30 min following IPTG induction; these aliquots were centrifuged, resuspended in 50 l of sodium dodecyl sulfate (SDS) gel sample buffer, and frozen at Ϫ20°C. Following incubation of the samples at 70°C for 5 min, 6 l of each sample was run on SDS-10% polyacrylamide gels (4) . Protein band intensities subsequent to Coomassie blue staining confirmed that the TMEV fusion protein fragments were the dominant proteins expressed in their respective cultures and that the optimal times for harvesting cultures to acquire optimal yield were 1.5 to 2.0 h postinduction.
Cell lysis and hydrolysis. Three milliliters of induced cultures (prepared as described above for protein expression) was harvested by centrifugation (5,000 ϫ g for 5 min at 4°C [Sorvall RC-5B; DuPont Instruments, Wilmington, Del.]), washed once in 50 mM Tris-HCl (pH 8.0)-2 mM EDTA, and centrifuged again. The pelleted cells were resuspended in 100 l of fresh lysozyme solution (0.5 g/ml in 10 mM Tris [pH 8.0]), and the suspension was incubated for 1 h at room temperature. After one freeze-thaw cycle in ethanol-dry ice, the lysozyme was inactivated by boiling. NaOH was added to a final concentration of 1 N, and lysates were boiled at 100°C for various time increments ranging from 30 s to 10 min. Hydrolyzed lysates were neutralized with HCl, placed on ice, and adjusted to pH 7.0 to 7.6. Samples were centrifuged briefly to remove insoluble material prior to use in CTL assays.
Extraction of CNS-ILs and establishment of lines and clones. Resistant C57BL/10 mice were infected with TMEV by an intracerebral injection of the DA strain of TMEV at a dose of 2 ϫ 10 5 PFU in 10 l. This DA viral stock was propagated in BHK-2 cells and plaqued on L2 cells. Fresh CNS-ILs were obtained as previously described (18, 19) . Briefly, brains and spinal cords were harvested 7 days after infection, and cells were suspended by passage through fine-mesh stainless steel screens. Suspended cells were layered on a discontinuous Percoll (Pharmacia) gradient and centrifuged at 27,000 ϫ g for 30 min. The lymphocyte fraction of the gradient was collected, washed twice with RPMI 1640, and counted. CNS-IL lines were established by the technique described by Bergmann et al. (3) , which involved preincubation of CNS-ILs in plastic tissue culture vessels for 2 h at 37°C in order to remove adherent cells. Nonadherent cells were collected and mixed with 1.25 ϫ 10 4 C57SV fibroblasts transfected with the TMEV VP2 gene or with the left-hand portion (LP) of TMEV that includes the VP1, VP2, VP3, and VP4 genes (17) . These cells were grown in Iscove's medium plus 5% fetal calf serum and supernatant from rat splenocytes stimulated with concanavalin A as a source of interleukin-2. Limiting-dilution cloning was performed in 96-well plates (round bottom) with 20, 10, and 5 responders plus 10 4 irradiated VP2-or LP-transfected C57SV cells/well. CTL lines and clones were tested for specificity in a cell-mediated lympholysis (CML) assay as previously described (37) . Target cells for testing the specificity of CTL were 51 Cr-labeled C57SV cells and C57SV cells transfected with VP2. Two thousand targets were mixed with CTL in microtiter wells to yield effector-totarget (E:T) ratios that varied according to the tested CTL, and the plates were incubated for 4 h at 37°C. One hundred microliters of supernatant was harvested for counting in a gamma counter, and the 51 Cr release from labeled targets was determined by the following equation: % specific release ϭ experimental release Ϫ spontaneous release maximum release Ϫ spontaneous release ϫ 100
Maximum release and spontaneous release were the amounts of 51 Cr released during incubation with 2.5% Triton X-100 and medium alone, respectively; spontaneous release from RMA-S and fibroblast targets was routinely 10 to 20% of maximum release. Mean specific release (Ϯ standard errors) was determined for each E:T ratio, and standard errors were routinely Ͻ10% of the mean specific release. This standard CML assay was modified for RMA-S cells sensitized with peptides as described previously (23) . 51 Cr-labelled RMA-S cells were sensitized with peptides for 40 to 60 min at room temperature in Iscove's medium plus 10% fetal calf serum. CTL were added to yield the required E:T ratio for a 4-h incubation at 37°C. Specific peptide sensitization was calculated as the difference between the percentages of 51 Cr release with and without CTL. Peptide synthesis. Five peptides (VP2 112-121 , VP2 112-131 , VP2 121-140 , VP2 121-130 , and VP2 122-130 ) were synthesized on a Gilson AMS422 peptide synthesizer (Gilson Medical Electronics, Inc., Middleton, Wis.) by 9-fluorenylmethoxycarbonyl chemistry and purified by reverse-phase high-performance liquid chromatography. The purity and identity of the synthetic peptides were confirmed by mass spectrometry.
Peptide binding and class I stabilization assays. The specificity of synthetic peptide binding to K b and D b molecules of RMA-S cells was quantitated by a previously described stabilization assay (35) . RMA-S cells were incubated overnight at 26°C, sensitized with peptides at a final concentration of 50 M in the presence of Brefeldin A (BFA; 10 mg/ml; Sigma, St. Louis, Mo.) for 1 h at room temperature, washed, and incubated at 37°C for 2 h. Cells (3 ϫ 10 5 ) were washed and stained for K b or D b class I expression by using Y-3 and B22.249 monoclonal antibodies (in appropriate dilutions of ascites), respectively (13, 14) . Antibodylabelled cells were incubated for 30 min with a fluorescein isothiocyanate-conjugated anti-mouse immunoglobulin antibody. All incubations were performed in 1% bovine serum albumin-phosphate-buffered saline at 4°C. The cells were washed, and the analysis of 10 4 gated events per sample was performed on a FACScan flow cytometer (Beckton Dickinson Co, Mountain View, Calif.). The 50% stabilization concentration corresponds to the peptide concentration producing half-maximal upregulation of class I molecules. The relative dissociation rate of bound peptide from cell surface class I D b was estimated by incubating (3 ϫ 10 5 ) RMA-S cells (26°C overnight) with or without BFA (10 mg/ml) for 1 h at room temperature, after which they were incubated with peptide for 1 h at room temperature. Free peptides were washed away, and fresh medium was added to the cells for incubation at 37°C. At different time points, samples were collected and stained for D b complexes as described above. Samples not incubated at 37°C were taken as time zero.
RESULTS
Lytic activity of CTL with VP2-transfected C57SV cells. CTL lines and clones derived from CNS-IL populations were tested for specificity with C57SV cells transfected with the full-length VP2 gene. C57SV-VP2 transfectants were lysed by all CTL lines and clones with killing ranging from 20 to 49% (Table 1) . The clones and lines used in the experiments described here are indicated in Fig. 2 . No significant lysis of nontransfected C57SV fibroblasts was observed. These results are consistent with previous observations pointing toward a prominent response of B6 mice to VP2 (17) .
VP2 fusion protein yields immunogenic peptides. Based on these results, the VP2 gene was selected for construction of an inducible fusion protein as described above. Since H2 class I molecules preferentially bind 8-to 10-amino-acid peptides, it was necessary to cleave the induced fusion proteins prior to sensitization of RMA-S targets. RMA-S cells have defective TAP function, with the result that their class I molecules are unstable unless complexed with peptide or incubated at 26°C (21, 35) . We chose to follow the previously described approach (5) to randomly hydrolyze the VP2 fusion protein with NaOH, neutralize the peptide mixture, and sensitize RMA-S cell targets with the peptide supernatant. Since that previous report cited the variable sensitivity of peptides to base hydrolysis (5), we subjected the full-length VP2 fusion protein to base hydro- Fig. 1] ) from the respective transformants were hydrolyzed with NaOH for 1 min and were used to sensitize RMA-S cells for lysis by the C4 CTL clone (Fig. 2) . No lysis was observed with fractions F3 to F7, but a significant level of lysis was observed with fragment F8 (52%). Further, lysis was maintained with all hydrolyzed fragments larger than F8. Fragment F8 differed from the F7 fragment by the addition of VP2 amino acids 121 to 140, localizing the region of an immunogenic VP2 epitope to amino acids 112 to 140 in that only part of the peptide may have been included in fragment F7. The recognition of fragments F8 to F10 was not restricted to the C4 CTL clone. VP2-specific CTL clone D2, a pool of CTL clones G10 and F5, and two VP2-specific CTL lines (9/95 and 269/95) recognized RMA-S targets sensitized with alkali-digested VP2 fusion protein fragments F8, F9, and F10 (Fig. 3) . Alkali-digested Escherichia coli transformants containing vector without insert and VP2 fusion protein fragments F6 and F7 did not sensitize RMA-S targets for lysis by these clones and lines.
Localization of an active 10-amino-acid peptide. Two 20 residue overlapping synthetic peptides (VP2 112-131 and VP2 121-140 ) were synthesized to provide an 11-residue overlap. VP2 112-131 included the last 10 amino acids of F7. Both peptides sensitized RMA-S target cells for lysis by VP2-specific CTL clone C4 (Fig. 4) , suggesting that the active peptide was included in the 11-amino-acid overlap. Based on the preponderance of Asn residues at position five of D b -binding peptides (30), a 10-amino-acid peptide comprised of VP2 residues 112 to 121 was synthesized and tested for sensitization (Fig. 4) . No lysis was observed with VP2 112-121 in the parallel analysis with the two active overlapping 20-amino-acid peptides. The lack of a second Asn residue in the overlap region suggested that the FIG. 2. CML assay of 10 NaOH-hydrolyzed VP2 fragments with CTL clone C4 derived from CNS-IL populations 7 days after TMEV infection of B10 mice. Bacterial lysates (10 l) containing hydrolyzed fragments of VP2 of increasing size (amino acid locations indicated in parentheses) were mixed with 51 Crlabelled RMA-S targets and clone C4 CTL (E:T ratio, 40:1). Spontaneous release of 51 Cr from RMA-S targets was 9% of maximum release. (34) . Therefore, we synthesized two peptides that had the VFM sequence at carboxy termini and included residues 121 to 130 and 122 to 130. The two peptides were titrated for sensitization of RMA-S cells for lysis by freshly harvested CNS-ILs from TMEV-infected B10 mice (Fig. 5) . CNS-IL effectors were chosen to evaluate the recognition of these peptides by CTL; since they had not been subjected to long-term in vitro manipulation. Although both peptides sensitized RMA-S cells for lysis at 1 M, only FHAGSLLVFM maintained activity throughout the titration, with Ͼ50% maximal lysis still observed at a concentration of 1 fM. The activity of the VP2 122-130 peptide rapidly declined at 100 and 10 nM. These results indicate that the FHAGSLLVFM peptide is effectively recognized by CNS-IL CTL despite its lack of a canonical anchor residue in the fifth amino acid position. ) , and no peptide, after which the cells were pelleted and the medium was replaced with fresh medium. The cells were transferred to 37°C, and aliquots were removed at individual time points ranging from 0 to 6 h for staining with B22.249 as described above. Peptide pulsing and subsequent incubation at 37°C were performed in the absence or presence of BFA (10 g/ml). (Fig. 7) . Consistent with the results of flow cytometry experiments described above, we observed an increase in VP2 121-130 activity after 1 h at 37°C in the absence of BFA, which was not observed in the presence of BFA. Furthermore, detectable, sensitizing activity was still observed after 8 h of incubation at 37°C.
DISCUSSION
Alkali-hydrolyzed products of a panel of TMEV-VP2 recombinant fusion proteins were successfully screened in CTL assays to identify a unique H2D b -restricted CTL epitope encoded by the VP2 region of the DA strain of TMEV. The identified peptide, VP2 121-130 (FHAGSLLVFM), binds H2D b molecules and is recognized by freshly harvested CNS-IL CTL from TMEV-infected mice. The truncation of this peptide to HAGSLLVFM lowers both the ability to sensitize targets for lysis and the affinity for D b molecules. It was important to confirm the identification of the synthetic peptides by using CTL that were harvested directly from TMEV-infected mouse brains. Potential problems with drift and selection during in vitro stimulation and expansion of CTL, which could conceivably give either false-negative or -positive results, were thus avoided.
The alkali hydrolysis method employed here was demonstrated previously to be useful for epitope analysis with the identification of an L d -restricted nonamer from E. coli ␤-galactosidase that is known to be endogenously processed and presented (11) . This method provides a rapid and inexpensive means to potentially produce all immunogenic epitopes for any gene (prokaryotic or eukaryotic) for which the sequence is known. The ability to restrict the origin of the peptide pool is clearly advantageous over the use of peptide libraries as an epitope source. For our purposes, fusion protein constructs were selected because the small VP2 protein fragments could potentially be unstable in an expression system. Further, neither the non-VP2 portion of the fusion protein nor the bacterial proteins interfered with our assays as sources of immunogenic peptides or toxicity.
TMEV-infected mice provide a model for virus-induced demyelination with resistance and susceptibility to demyelination mapping to polymorphic genes linked to the H2 complex. (17) . A search for immunogenic peptides in the remainder of the VP2 protein as well as the remaining TMEV genes is in progress.
Although the VP2 121-130 peptide binds to D b molecules and is recognized by anti-TMEV CTL, it is not certain that this is the exact peptide that is processed by either TMEV-infected cells in the CNS or fibroblasts transfected with the VP2 gene. The increase in both VP2 121-130 -D b complexing and sensitization activity in the absence of BFA suggests a potential role for endocytosis and processing of VP2 121-130 for augmented presentation in the absence of BFA. There is precedent for such endocytosis and processing of antigens for presentation by class I molecules (16) . The reduction in sensitizing activity to the micromolar range associated with removal of the Phe at residue 1 suggests that the naturally processed peptide is not HAGSLLVFM; this assumption is based on the observation that peptides derived from D b molecules of 10 8 fibroblasts transfected with VP2 and separated by high-performance liquid chromatography sensitize targets for lysis by TMEV-specific CTL (data not shown). However, we have not investigated the activity of the FHAGSLLVF peptide differing from 51 Cr-labelled RMA-S cells (2 ϫ 10 3 /well) were cultured at room temperature in the presence (open symbols) or absence (closed symbols) of BFA (10 mg/ml) for 1 h before addition of the VP2 121-130 peptide (1 nM). After 1 h of incubation at room temperature, the medium was discarded, fresh medium with or without BFA was added, and the cultures were transferred to 37°C. Samples were harvested at time points ranging from 1 to 8 h and, after the medium was changed, a 4-h CML assay was performed with CNS-IL CTL (E:T ratio, 50:1). murine picornaviruses. An alignment of the VP2 121-130 sequence with database sequences identified two TMEV strains that differ in this immunogenic region by only single amino acids. One of the variants, the Vilyuisk virus, is a poorly characterized, highly divergent Theiler's virus (27) and encodes the FHAGSLLVFL peptide that differs from VP2 121-130 by an MϾL interchange at position 10. The highly virulent GDVII strain of Theiler's virus encodes the FHAGSLLVLM peptide (FϾL interchange at position 9) (26). All tested mouse strains, including those of the b haplotype, rapidly develop fatal encephalitis when infected with low dosages of GDVII (20, 22) . -binding peptides have an Asn at position 5, and the combination of alternative amino acids at positions important for binding and T-cell receptor recognition can endow a peptide with the ability both to bind to class I molecules and to be efficiently recognized by CTL. This conclusion supports the utility of class I motif information only as a valuable guide, and the principal reliance on motif data may result in a failure to identify immunogenic epitopes.
